GlassScriptPhysician profile
Lihong Wu
NPI 1932128410
$3,249.65
in general payments reported to CMS, 2019-2025
39 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,833 · 2020: $746 · 2021: $315 · 2022: $182 · 2023: $21.00 · 2024: $36.95 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.66 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $241.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $231.94 | 2019-2021 | |
| Pfizer INC. | $207.40 | 2019-2022 | |
| Janssen Biotech, INC. | $190.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $188.41 | 2019 | |
| Genentech USA, INC. | $171.32 | 2019-2021 | |
| Amgen INC. | $155.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $151.54 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $149.79 | 2019-2020 | |
| Lilly USA, LLC | $140.74 | 2019-2022 | |
| Celgene Corporation | $123.16 | 2019-2024 | Reblozyl |
| Blueprint Medicines Corporation | $116.71 | 2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $97.97 | 2019-2020 | |
| Exelixis INC. | $97.89 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $92.38 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $91.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.44 | 2019-2021 | |
| Clovis Oncology, INC. | $78.33 | 2019-2020 | |
| Incyte Corporation | $65.47 | 2020-2021 | |
| Genzyme Corporation | $60.55 | 2019-2021 | |
| Tersera Therapeutics LLC | $51.60 | 2019 | |
| Seagen INC. | $48.30 | 2020 | |
| Foundation Medicine, INC. | $46.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.03 | 2019-2021 | |
| Daiichi Sankyo INC. | $40.23 | 2021 | |
| Gilead Sciences, INC. | $40.21 | 2019 | |
| Tesaro, INC. | $28.93 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $26.80 | 2019 | |
| Emmaus Medical, INC. | $23.48 | 2020 | |
| Amag Pharmaceuticals, INC. | $23.11 | 2019 | |
| Glaxosmithkline, LLC. | $22.26 | 2020 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Karyopharm Therapeutics INC. | $19.41 | 2021 | |
| Partner Therapeutics, INC. | $18.09 | 2020 | |
| Eisai INC. | $16.92 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.59 | 2019 | |
| Innate Pharma, INC | $12.97 | 2020 | |
| Array Biopharma INC | $12.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $5.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lihong Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.